Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Acq. announced
Appointed director
Inv. presentation
Midatech Pharma US Inc. (DARA) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/04/2015 8-K Quarterly results
12/02/2015 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "DARA BioSciences Announces Stockholder Approval of Merger with Midatech RALEIGH, NC -- – December 2, 2015 -- DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that its stockholders have approved the adoption of the previously announced merger agreement by and among DARA, Midatech Pharma PLC and certain other parties thereto. Pursuant to the merger agreement, upon completion of the contemplated merger, DARA will become a wholly owned subsidiary of Midatech. The merger remains subject to customary closing conditions and is expected to close in the next week. ..."
11/18/2015 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11/02/2015 8-K Quarterly results
Docs: "DARA BioSciences Announces Third Quarter 2015 Results Record Revenues for Q3 Company Reaffirms 2015 full year Guidance of $3.7 Million in Net Revenues Company Provides Update on Merger Agreement with Midatech Pharma PLC RALEIGH, NC -- – November 2, 2015 -- DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its third quarter 2015 results. Third Quarter 2015 Financial Snapshot DARA reported net revenues of $1.181 million for the third quarter ended September 30, 2015 based on gross product sales in excess of $1.5 million, as compared to net revenues of $597.8 ..."
08/12/2015 8-K Quarterly results
Docs: "DARA BioSciences Announces Second Quarter 2015 Results Record Revenues for Q2 Company Reaffirms 2015 full year Guidance of $3.7 Million in Net Revenues Company Provides Update on Merger Agreement with Midatech Pharma PLC RALEIGH, NC -- – August 12 -- DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its second quarter 2015 results. Second Quarter 2015 Financial Snapshot DARA reported net revenues of $990.8 thousand for the second quarter ended June 30, 2015 based on gross product sales in excess of $1.4 million, as compared to net revenues of $409.4 thousan..."
06/04/2015 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, among DARA BioSciences, Inc., Midatech Pharma, PLC, Merlin Acquisition Sub, Inc., Duke Acquisition Sub, Inc. and Shareholder Representative Services, LLC",
"Form of Contingent Value Rights Agreement",
"Form of Voting Agreement",
"- DARA’s Commercial Organization Key Driver of Agreement - Combined Organization Provides Pipeline of Oncology Products for U.S. Commercialization"
05/19/2015 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
05/13/2015 8-K Quarterly results
Docs: "DARA BIOSCIENCES ANNOUNCES FIRST QUARTER 2015 RESULTS Company to provide inaugural 2015 revenue guidance based upon continued commercial progress Raleigh, NC – – DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its first quarter 2015 results. First Quarter 2015 Financial Snapshot DARA reported net revenues of $652.2 thousand for the first quarter ended March 31, 2015 based on gross product sales in excess of $850 thousand, as compared to net revenues of $161.5 thousand for the first quarter ended March 31, 2014, a year over year increase of 304%. The incre..."
03/10/2015 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "DARA BIOSCIENCES ANNOUNCES THE ACQUISITION OF EXCLUSIVE NORTH AMERICAN RIGHTS TO ORAVIG® , FROM ONXEO S.A. - DARA signs agreement with Mission Pharmacal to promote Oravig in the Primary Care Market - DARA to promote Oravig in the Oncology Market - Deal significantly strengthens DARA’s oncology supportive care portfolio"
03/03/2015 8-K Quarterly results
Docs: "DARA BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2014 RESULTS Strong Annual Revenue Growth Driven By Execution of Commercial Sales Strategy Raleigh, NC – – DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its financial results for the fourth quarter and full year ended December 31, 2014. The Company also provided a business update on its fourth quarter 2014 operational and commercial highlights. Fourth Quarter 2014 Financial Snapshot DARA reported net revenues of $1.89 million for the full year ended December 31, 2014 based on gross product sales of ..."
01/20/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, by and between DARA BioSciences, Inc. and Christopher G. Clement",
"Employment Agreement, by and between DARA BioSciences, Inc. and David J. Drutz",
"Employment Agreement, by and between DARA BioSciences, Inc. and David Tousley"
01/06/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Corporate Contact:"
12/15/2014 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Exchange and Amendment Agreement",
"Common Stock Purchase Warrant with respect to 125,000 shares of common stock of DARA BioSciences, Inc",
"Common Stock Purchase Warrant with respect to 175,000 shares of common stock of DARA BioSciences, Inc"
11/21/2014 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11/05/2014 8-K Quarterly results
Docs: "DARA BIOSCIENCES ANNOUNCES THIRD QUARTER 2014 RESULTS Continued strong revenue growth driven by sales momentum across broad portfolio Raleigh, NC – – DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its third quarter 2014 results. Third Quarter 2014 Financial Snapshot DARA reported net revenues of $597.8 thousand for the third quarter ended September 30, 2014 based on gross product sales in excess of $690 thousand, as compared to net revenues of $138.9 thousand for the third quarter ended September 30, 2013, a year over year increase of 330%. The increase i..."
08/12/2014 8-K Quarterly results
Docs: "DARA BIOSCIENCES ANNOUNCES SECOND QUARTER 2014 RESULTS Record Quarterly Sales Driven By Commercial Success Raleigh, NC – – DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its second quarter 2014 results. Second Quarter 2014 Financial Snapshot DARA reported net revenues of $409.4 thousand for the second quarter ended June 30, 2014 based on gross product sales in excess of $500 thousand, as compared to net revenues of approximately $76.9 thousand for the second quarter ended June 30, 2013, a year over year increase of 432%. The increase in revenues was prima..."
08/05/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/10/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated Employment Agreement, by and between DARA BioSciences, Inc. and David L. Tousley"
06/17/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Current President and COO Christopher G. Clement named CEO; David J. Drutz, MD transitions to Executive Chairman and retains CMO role; Haywood D. Cochrane, Jr. assumes role of Vice Chairman"
06/16/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "DARA BioSciences’ KRN5500 Granted Orphan Drug Designation by FDA For Treatment of Multiple Myeloma Second Orphan Drug Designation Received in 2014 for Key Development Asset"
06/05/2014 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Designation of Preferences, Rights and Limitations of Series C-1 Convertible Preferred Stock"
05/30/2014 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Placement Agent Agreement, by and between DARA BioSciences, Inc. and Ladenburg Thalmann & Co. Inc",
"Form of Certificate of Designation of Preferences, Rights and Limitations of Series C-1 Convertible Preferred Stock",
"Form of Five-Year Warrant",
"Form of Thirteen-Month Warrant",
"Form of Securities Purchase Agreement, between DARA BioSciences and the investors signatory thereto",
"Media David Connolly LaVoieHealthSciences 617-374-8800, Ext. 108 [email protected] Corporate Jim Polson FTI Consulting 312 553 6730 [email protected]&#65279"
05/19/2014 8-K Submission of Matters to a Vote of Security Holders
05/12/2014 8-K Quarterly results
Docs: "DARA BIOSCIENCES ANNOUNCES FIRST QUARTER 2014 RESULTS Company Implemented New Nationwide Sales Force in January; Complemented Oncology Supportive Care Product Portfolio Raleigh, NC – – DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its first quarter 2014 results. First Quarter 2014 Financial Snapshot For the first quarter ended March 31, 2014, DARA reported a net loss attributable to controlling interest of , or per share as compared to a net loss attributable to controlling interest of , or per share for the first quarter ended March 31, 2013. As of Mar..."
02/25/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "DARA BioSciences Regains Compliance with NASDAQ Bid Price Requirement"
02/25/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "DARA BioSciences’ KRN5500 Receives Orphan Drug Designation from FDA -Novel Non-opioid Therapeutic in Phase 2 to Treat Chronic Chemotherapy-Induced Peripheral Neuropathy- -Existing FDA Fast Track Designation-"
02/12/2014 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Placement Agent Agreement, between DARA BioSciences, Inc. and Ladenburg Thalmann & Co. Inc",
"Form of Warrant",
"Opinion of Lowenstein Sandler LLP",
"FORM OF SECURITIES PURCHASE AGREEMENT",
"Press Release of DARA BioSciences, Inc."
02/10/2014 8-K Investor presentation
02/06/2014 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "CERTIFICATE OF AMENDMENT",
"DARA BioSciences Announces 1-for-5 Reverse Split"
02/04/2014 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "DARA REPORTS 2013 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS AND COMMERCIAL BUSINESS UPDATE -Continued execution of commercial strategy yields growth in 4Q revenues- -Expansion of national sales force in January 2014 and synergistic oncology supportive care portfolio expected to support increased market penetration and revenue growth-"
11/14/2013 8-K Investor presentation, Quarterly results
Docs: "DARA REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS AND HIGHLIGHTS COMMERCIAL MOMENTUM ON SYNERGISTIC ONCOLOGY SUPPORTIVE CARE PRODUCT PORTFOLIO -Refined commercial strategy launched Q2 2013 increases sales frequency, raises product awareness and yields encouraging progress across product portfolio fueling significant growth in Q3 revenues- -Recent Alamo and Mission Pharmacal agreements to expand national sales force from 5 to 20 representatives and complement synergistic supportive care products portfolio- -Company poised for robust revenue generation in 2014-",
"SLIDE PRESENTATION"
11/12/2013 8-K Form 8-K - Current report
10/29/2013 8-K Investor presentation
Docs: "Investor Presentation dated October 2013"
10/28/2013 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "DARA BioSciences Announces Sales Force Expansion and Agreement with Mission Pharmacal in the Oncology Market -Signs agreement, exclusive to oncology market, with Mission Pharmacal- -Signs agreement with Alamo Pharma Services for a national sales team to promote DARA’s products with three additional Mission supportive care products- -Results of increased sales frequency support national field force expansion-"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy